Nuveen LLC Purchases Shares of 236,947 Kura Oncology, Inc. $KURA

Key Points

• Nuveen LLC has acquired a new stake in Kura Oncology, purchasing 236,947 shares for approximately $1,564,000, marking a 0.27% ownership as per their latest SEC filing.
• Kura Oncology's stock has faced a setback, currently trading at $7.90 and down 2.1%, with a market cap of $685.72 million and a twelve-month trading range between $5.41 and $21.57.
• Analysts have mixed opinions on Kura Oncology's stock, with a consensus rating of "Moderate Buy" and a target price set at $24.10, though forecasts suggest potential earnings per share could reach -2.44 for the current year.

Nuveen LLC acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 236,947 shares of the company's stock, valued at approximately $1,564,000. Nuveen LLC owned about 0.27% of Kura Oncology as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. boosted its position in Kura Oncology by 44.6% in the 1st quarter. Invesco Ltd. now owns 97,216 shares of the company's stock valued at $642,000 after buying an additional 29,978 shares during the last quarter. Vanguard Group Inc. boosted its position in Kura Oncology by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after buying an additional 129,337 shares during the last quarter. US Bancorp DE boosted its position in Kura Oncology by 79.3% in the 1st quarter. US Bancorp DE now owns 39,627 shares of the company's stock valued at $262,000 after buying an additional 17,523 shares during the last quarter. XTX Topco Ltd boosted its position in Kura Oncology by 115.1% in the 1st quarter. XTX Topco Ltd now owns 44,455 shares of the company's stock valued at $293,000 after buying an additional 23,786 shares during the last quarter. Finally, Corton Capital Inc. boosted its position in Kura Oncology by 123.0% in the 1st quarter. Corton Capital Inc. now owns 25,300 shares of the company's stock valued at $167,000 after buying an additional 13,956 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have commented on KURA shares. Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Guggenheim assumed coverage on Kura Oncology in a research report on Thursday. They issued a "neutral" rating on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Friday, June 20th. Finally, Mizuho reduced their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and an average price target of $24.10.

Kura Oncology Trading Down 5.4%

Kura Oncology stock traded down $0.46 during mid-day trading on Thursday, hitting $7.98. 363,489 shares of the company's stock were exchanged, compared to its average volume of 1,457,564. The firm has a market capitalization of $692.23 million, a P/E ratio of -3.53 and a beta of 0.19. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.40. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. The company's 50 day simple moving average is $6.57 and its 200-day simple moving average is $6.58.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. On average, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.